Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype.

Deligne C, Murdamoothoo D, Gammage AN, Gschwandtner M, Erne W, Loustau T, Marzeda AM, Carapito R, Paul N, Velázquez-Quesada I, Mazzier I, Sun Z, Orend G, Midwood KS.

Cancer Immunol Res. 2020 Jan 15. pii: canimm.0276.2019. doi: 10.1158/2326-6066.CIR-19-0276. [Epub ahead of print]

PMID:
31941671
2.

Functionalized Tobacco Mosaic Virus Coat Protein Monomers and Oligomers as Nanocarriers for Anti-Cancer Peptides.

Gamper C, Spenlé C, Boscá S, van der Heyden M, Erhardt M, Orend G, Bagnard D, Heinlein M.

Cancers (Basel). 2019 Oct 22;11(10). pii: E1609. doi: 10.3390/cancers11101609.

3.

Tenascin-C increases lung metastasis by impacting blood vessel invasions.

Sun Z, Velázquez-Quesada I, Murdamoothoo D, Ahowesso C, Yilmaz A, Spenlé C, Averous G, Erne W, Oberndorfer F, Oszwald A, Kain R, Bourdon C, Mangin P, Deligne C, Midwood K, Abou-Faycal C, Lefebvre O, Klein A, van der Heyden M, Chenard MP, Christofori G, Mathelin C, Loustau T, Hussenet T, Orend G.

Matrix Biol. 2019 Oct;83:26-47. doi: 10.1016/j.matbio.2019.07.001. Epub 2019 Jul 6.

4.

Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma.

Mammadova-Bach E, Rupp T, Spenlé C, Jivkov I, Shankaranarayanan P, Klein A, Pisarsky L, Méchine-Neuville A, Cremel G, Kedinger M, De Wever O, Ambartsumian N, Robine S, Pencreach E, Guenot D, Simon-Assmann P, Goetz JG, Orend G, Lefebvre O.

Biol Cell. 2018 Jun 15. doi: 10.1111/boc.201800007. [Epub ahead of print]

PMID:
29907957
5.

Periostin Limits Tumor Response to VEGFA Inhibition.

Keklikoglou I, Kadioglu E, Bissinger S, Langlois B, Bellotti A, Orend G, Ries CH, De Palma M.

Cell Rep. 2018 Mar 6;22(10):2530-2540. doi: 10.1016/j.celrep.2018.02.035.

6.

Investigating cell-type specific functions of tenascin-C.

Murdamoothoo D, Schwenzer A, Kant J, Rupp T, Marzeda A, Midwood K, Orend G.

Methods Cell Biol. 2018;143:401-428. doi: 10.1016/bs.mcb.2017.08.023. Epub 2017 Dec 1.

PMID:
29310789
7.

How to detect and purify tenascin-C.

Giblin SP, Murdamoothoo D, Deligne C, Schwenzer A, Orend G, Midwood KS.

Methods Cell Biol. 2018;143:371-400. doi: 10.1016/bs.mcb.2017.08.022. Epub 2017 Nov 26.

PMID:
29310788
8.

Tenascin-C Promotes Tumor Cell Migration and Metastasis through Integrin α9β1-Mediated YAP Inhibition.

Sun Z, Schwenzer A, Rupp T, Murdamoothoo D, Vegliante R, Lefebvre O, Klein A, Hussenet T, Orend G.

Cancer Res. 2018 Feb 15;78(4):950-961. doi: 10.1158/0008-5472.CAN-17-1597. Epub 2017 Dec 19.

9.

Counterbalancing anti-adhesive effects of Tenascin-C through fibronectin expression in endothelial cells.

Radwanska A, Grall D, Schaub S, Divonne SBF, Ciais D, Rekima S, Rupp T, Sudaka A, Orend G, Van Obberghen-Schilling E.

Sci Rep. 2017 Oct 6;7(1):12762. doi: 10.1038/s41598-017-13008-9.

10.

Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and Anti-angiogenic Signaling.

Rupp T, Langlois B, Koczorowska MM, Radwanska A, Sun Z, Hussenet T, Lefebvre O, Murdamoothoo D, Arnold C, Klein A, Biniossek ML, Hyenne V, Naudin E, Velazquez-Quesada I, Schilling O, Van Obberghen-Schilling E, Orend G.

Cell Rep. 2016 Dec 6;17(10):2607-2619. doi: 10.1016/j.celrep.2016.11.012.

11.

Tenascin-C at a glance.

Midwood KS, Chiquet M, Tucker RP, Orend G.

J Cell Sci. 2016 Dec 1;129(23):4321-4327. Epub 2016 Nov 10. Review.

12.

Stem cells and matrix.

Oskarsson T, Orend G.

Int J Biochem Cell Biol. 2016 Dec;81(Pt A):165. doi: 10.1016/j.biocel.2016.10.012. Epub 2016 Oct 19. No abstract available.

PMID:
27771438
13.

Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.

Mammadova-Bach E, Zigrino P, Brucker C, Bourdon C, Freund M, De Arcangelis A, Abrams SI, Orend G, Gachet C, Mangin PH.

JCI Insight. 2016 Sep 8;1(14):e88245. doi: 10.1172/jci.insight.88245.

14.

Inhibition of PlexA1-mediated brain tumor growth and tumor-associated angiogenesis using a transmembrane domain targeting peptide.

Jacob L, Sawma P, Garnier N, Meyer LA, Fritz J, Hussenet T, Spenlé C, Goetz J, Vermot J, Fernandez A, Baumlin N, Aci-Sèche S, Orend G, Roussel G, Crémel G, Genest M, Hubert P, Bagnard D.

Oncotarget. 2016 Sep 6;7(36):57851-57865. doi: 10.18632/oncotarget.11072.

15.

Inhibition of primary breast tumor growth and metastasis using a neuropilin-1 transmembrane domain interfering peptide.

Arpel A, Gamper C, Spenlé C, Fernandez A, Jacob L, Baumlin N, Laquerriere P, Orend G, Crémel G, Bagnard D.

Oncotarget. 2016 Aug 23;7(34):54723-54732. doi: 10.18632/oncotarget.10101.

16.

Autonomous Extracellular Matrix Remodeling Controls a Progressive Adaptation in Muscle Stem Cell Regenerative Capacity during Development.

Tierney MT, Gromova A, Sesillo FB, Sala D, Spenlé C, Orend G, Sacco A.

Cell Rep. 2016 Mar 1;14(8):1940-52. doi: 10.1016/j.celrep.2016.01.072. Epub 2016 Feb 18.

17.

A hypermorphic epithelial β-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations.

Buchert M, Rohde F, Eissmann M, Tebbutt N, Williams B, Tan CW, Owen A, Hirokawa Y, Gnann A, Orend G, Orner G, Dashwood RH, Heath JK, Ernst M, Janssen KP.

Dis Model Mech. 2015 Nov;8(11):1361-73. doi: 10.1242/dmm.019844. Epub 2015 Aug 6.

18.

Special issue of Cell Adhesion & Migration on Tenascins: Defining their role in tissue homeostasis and cancer.

Midwood K, Orend G.

Cell Adh Migr. 2015;9(1-2):1-3. doi: 10.1080/19336918.2015.1014279. No abstract available.

19.

Spatial organization of the tenascin-C microenvironment in experimental and human cancer.

Spenlé C, Gasser I, Saupe F, Janssen KP, Arnold C, Klein A, van der Heyden M, Mutterer J, Neuville-Méchine A, Chenard MP, Guenot D, Esposito I, Slotta-Huspenina J, Ambartsumian N, Simon-Assmann P, Orend G.

Cell Adh Migr. 2015;9(1-2):4-13. doi: 10.1080/19336918.2015.1005452.

20.

Tenascin-C: Exploitation and collateral damage in cancer management.

Spenlé C, Saupe F, Midwood K, Burckel H, Noel G, Orend G.

Cell Adh Migr. 2015;9(1-2):141-53. doi: 10.1080/19336918.2014.1000074. Review.

21.

The laminin response in inflammatory bowel disease: protection or malignancy?

Spenlé C, Lefebvre O, Lacroute J, Méchine-Neuville A, Barreau F, Blottière HM, Duclos B, Arnold C, Hussenet T, Hemmerlé J, Gullberg D, Kedinger M, Sorokin L, Orend G, Simon-Assmann P.

PLoS One. 2014 Oct 27;9(10):e111336. doi: 10.1371/journal.pone.0111336. eCollection 2014.

22.

Phosphonated chelates for nuclear imaging.

Abada S, Lecointre A, Christine C, Ehret-Sabatier L, Saupe F, Orend G, Brasse D, Ouadi A, Hussenet T, Laquerrière P, Elhabiri M, Charbonnière LJ.

Org Biomol Chem. 2014 Dec 21;12(47):9601-20. doi: 10.1039/c4ob01514b. Epub 2014 Oct 23.

PMID:
25338628
23.

AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients.

Langlois B, Saupe F, Rupp T, Arnold C, van der Heyden M, Orend G, Hussenet T.

Oncotarget. 2014 Nov 15;5(21):10529-45.

24.

Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis.

Arpel A, Sawma P, Spenlé C, Fritz J, Meyer L, Garnier N, Velázquez-Quesada I, Hussenet T, Aci-Sèche S, Baumlin N, Genest M, Brasse D, Hubert P, Crémel G, Orend G, Laquerrière P, Bagnard D.

Cell Rep. 2014 Sep 25;8(6):1714-1721. doi: 10.1016/j.celrep.2014.07.044. Epub 2014 Sep 15.

25.

Loss of SPARC protects hematopoietic stem cells from chemotherapy toxicity by accelerating their return to quiescence.

Ehninger A, Boch T, Medyouf H, Müdder K, Orend G, Trumpp A.

Blood. 2014 Jun 26;123(26):4054-63. doi: 10.1182/blood-2013-10-533711. Epub 2014 May 15.

PMID:
24833352
26.

Tenascins in stem cell niches.

Chiquet-Ehrismann R, Orend G, Chiquet M, Tucker RP, Midwood KS.

Matrix Biol. 2014 Jul;37:112-23. doi: 10.1016/j.matbio.2014.01.007. Epub 2014 Jan 25. Review.

27.

Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model.

Saupe F, Schwenzer A, Jia Y, Gasser I, Spenlé C, Langlois B, Kammerer M, Lefebvre O, Hlushchuk R, Rupp T, Marko M, van der Heyden M, Cremel G, Arnold C, Klein A, Simon-Assmann P, Djonov V, Neuville-Méchine A, Esposito I, Slotta-Huspenina J, Janssen KP, de Wever O, Christofori G, Hussenet T, Orend G.

Cell Rep. 2013 Oct 31;5(2):482-92. doi: 10.1016/j.celrep.2013.09.014. Epub 2013 Oct 17.

28.

Synthesis of an activated phosphonated bifunctional chelate with potential for PET imaging and radiotherapy.

Christine C, Koubemba M, Shakir S, Clavier S, Ehret-Sabatier L, Saupe F, Orend G, Charbonnière LJ.

Org Biomol Chem. 2012 Dec 14;10(46):9183-90. doi: 10.1039/c2ob26452h. Epub 2012 Oct 22.

PMID:
23086384
29.

Laminin α5 guides tissue patterning and organogenesis.

Spenlé C, Simon-Assmann P, Orend G, Miner JH.

Cell Adh Migr. 2013 Jan-Feb;7(1):90-100. doi: 10.4161/cam.22236. Epub 2012 Oct 17. Review.

30.

Abnormal Wnt and PI3Kinase signaling in the malformed intestine of lama5 deficient mice.

Ritié L, Spenlé C, Lacroute J, Bolcato-Bellemin AL, Lefebvre O, Bole-Feysot C, Jost B, Klein A, Arnold C, Kedinger M, Bagnard D, Orend G, Simon-Assmann P.

PLoS One. 2012;7(5):e37710. doi: 10.1371/journal.pone.0037710. Epub 2012 May 30.

31.

Functional role of laminin α1 chain during cerebellum development.

Heng C, Lefebvre O, Klein A, Edwards MM, Simon-Assmann P, Orend G, Bagnard D.

Cell Adh Migr. 2011 Nov-Dec;5(6):480-9. doi: 10.4161/cam.5.6.19191.

32.

The adhesion modulating properties of tenascin-W.

Brellier F, Martina E, Chiquet M, Ferralli J, van der Heyden M, Orend G, Schittny JC, Chiquet-Ehrismann R, Tucker RP.

Int J Biol Sci. 2012;8(2):187-94. Epub 2011 Dec 20.

33.

Dysregulation of laminins in intestinal inflammation.

Spenlé C, Hussenet T, Lacroute J, Lefebvre O, Kedinger M, Orend G, Simon-Assmann P.

Pathol Biol (Paris). 2012 Feb;60(1):41-7. doi: 10.1016/j.patbio.2011.10.005. Epub 2011 Nov 17. Review.

PMID:
22100883
34.

Role of laminins in physiological and pathological angiogenesis.

Simon-Assmann P, Orend G, Mammadova-Bach E, Spenlé C, Lefebvre O.

Int J Dev Biol. 2011;55(4-5):455-65. doi: 10.1387/ijdb.103223ps. Review.

35.

Advances in tenascin-C biology.

Midwood KS, Hussenet T, Langlois B, Orend G.

Cell Mol Life Sci. 2011 Oct;68(19):3175-99. doi: 10.1007/s00018-011-0783-6. Epub 2011 Aug 5. Review.

36.

Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth.

Van Obberghen-Schilling E, Tucker RP, Saupe F, Gasser I, Cseh B, Orend G.

Int J Dev Biol. 2011;55(4-5):511-25. doi: 10.1387/ijdb.103243eo. Review.

37.

RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.

Wang Z, Collighan RJ, Gross SR, Danen EH, Orend G, Telci D, Griffin M.

J Biol Chem. 2010 Dec 17;285(51):40212-29. doi: 10.1074/jbc.M110.123703. Epub 2010 Oct 7.

38.

Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow.

Schaff M, Receveur N, Bourdon C, Wurtz V, Denis CV, Orend G, Gachet C, Lanza F, Mangin PH.

Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):117-24. doi: 10.1161/ATVBAHA.110.206375. Epub 2010 Jul 22. Erratum in: Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):e4.

PMID:
20651280
39.

Mutations in Lama1 disrupt retinal vascular development and inner limiting membrane formation.

Edwards MM, Mammadova-Bach E, Alpy F, Klein A, Hicks WL, Roux M, Simon-Assmann P, Smith RS, Orend G, Wu J, Peachey NS, Naggert JK, Lefebvre O, Nishina PM.

J Biol Chem. 2010 Mar 5;285(10):7697-711. doi: 10.1074/jbc.M109.069575. Epub 2010 Jan 4.

40.

The role of tenascin-C in tissue injury and tumorigenesis.

Midwood KS, Orend G.

J Cell Commun Signal. 2009 Dec;3(3-4):287-310. doi: 10.1007/s12079-009-0075-1. Epub 2009 Oct 17.

41.

Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.

Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B.

Nat Med. 2009 Jul;15(7):774-80. doi: 10.1038/nm.1987. Epub 2009 Jun 28.

PMID:
19561617
42.

Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment.

Lange K, Kammerer M, Saupe F, Hegi ME, Grotegut S, Fluri E, Orend G.

Cancer Res. 2008 Sep 1;68(17):6942-52. doi: 10.1158/0008-5472.CAN-08-0347.

43.

Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior.

Degen M, Brellier F, Kain R, Ruiz C, Terracciano L, Orend G, Chiquet-Ehrismann R.

Cancer Res. 2007 Oct 1;67(19):9169-79.

44.

Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization.

Lange K, Kammerer M, Hegi ME, Grotegut S, Dittmann A, Huang W, Fluri E, Yip GW, Götte M, Ruiz C, Orend G.

Cancer Res. 2007 Jul 1;67(13):6163-73.

45.

Tenascin-C induced signaling in cancer.

Orend G, Chiquet-Ehrismann R.

Cancer Lett. 2006 Dec 8;244(2):143-63. Epub 2006 Apr 24. Review.

PMID:
16632194
46.

CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis.

Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, Sleeman JP.

Cancer Res. 2005 Dec 1;65(23):10783-93.

47.

Potential oncogenic action of tenascin-C in tumorigenesis.

Orend G.

Int J Biochem Cell Biol. 2005 May;37(5):1066-83. Epub 2005 Jan 18. Review.

PMID:
15743679
48.

Growth promoting signaling by tenascin-C [corrected].

Ruiz C, Huang W, Hegi ME, Lange K, Hamou MF, Fluri E, Oakeley EJ, Chiquet-Ehrismann R, Orend G.

Cancer Res. 2004 Oct 15;64(20):7377-85. Erratum in: Cancer Res. 2004 Nov 15;64(22):8484.

49.

Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4.

Orend G, Huang W, Olayioye MA, Hynes NE, Chiquet-Ehrismann R.

Oncogene. 2003 Jun 19;22(25):3917-26.

PMID:
12813465
50.

Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation.

Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G.

Cancer Res. 2001 Dec 1;61(23):8586-94.

Supplemental Content

Support Center